LFLluis Fajas

Lluis Fajas

*This is an algorithmically generated author record based on publicly available information.

Lluis Fajas has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Abella

    INSERM, U540, Equipe Avenir, Montpellier F-34090, France,1 INSERM, U475, Montpellier F-34090, France,2 Centre Hospitalier Universitaire Arnaud de Villeneuve, Laboratoire de Biologie Cellulaire, Montpellier F-34090, France,3 Université Victor Ségalen, EA2406 Histologie et Pathologie Moléculaire, Bordeaux F-33076, France4

    2 shared publications
  • Irena Iankova

    INSERM, U540, Equipe Avenir, Montpellier F-34090, France,1 INSERM, U475, Montpellier F-34090, France,2 Centre Hospitalier Universitaire Arnaud de Villeneuve, Laboratoire de Biologie Cellulaire, Montpellier F-34090, France,3 Université Victor Ségalen, EA2406 Histologie et Pathologie Moléculaire, Bordeaux F-33076, France4

    2 shared publications
  • Jean-Sébastien Annicotte

    INSERM, U834, Montpellier, F-34298, France

    2 shared publications
  • Thierry Maudelonde

    INSERM, U540, Equipe Avenir, Montpellier F-34090, France,1 INSERM, U475, Montpellier F-34090, France,2 Centre Hospitalier Universitaire Arnaud de Villeneuve, Laboratoire de Biologie Cellulaire, Montpellier F-34090, France,3 Université Victor Ségalen, EA2406 Histologie et Pathologie Moléculaire, Bordeaux F-33076, France4

    2 shared publications
  • Anne Licznar

    Inserm Equipe Avenir, U540, 60 rue de Navacelles, Montpellier, France

    1 shared publication
  • Arnaud Pillon

    INSERM, U540, Equipe Avenir, Montpellier F-34090, France,1 INSERM, U475, Montpellier F-34090, France,2 Centre Hospitalier Universitaire Arnaud de Villeneuve, Laboratoire de Biologie Cellulaire, Montpellier F-34090, France,3 Université Victor Ségalen, EA2406 Histologie et Pathologie Moléculaire, Bordeaux F-33076, France4

    1 shared publication

Latest Publications

  • Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer

    by Jean-SébAstien Annicotte, Irena Iankova, StépHanie Miard, Vanessa Fritz, David Sarruf, Anna Abella, Marie-Laurence Berthe, DanièLE Noël, Arnaud Pillon, FrançoIs Iborra, et al.

    Peroxisome proliferator-activated receptor gamma (PPARgamma) might not be permissive to ligand activation in prostate cancer cells. Association of PPARgamma with repressing factors or posttranslational modifications in PPARgamma protein could explain the lack of effect of PPARgamma ligands in a recent randomized clinical trial. Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy. We show that the combination treatment impairs the bone-invasive potential of prostate cancer cells in mice. In addition, we demonstrate that expression of E-cadherin, a protein involved in the control of cell migration and invasion, is highly up-regulated in the presence of valproic acid and pioglitazone. We show that E-cadherin expression responds only to the combination treatment and not to single PPARgamma agonists, defining a new class of PPARgamma target genes. These results open up new therapeutic perspectives in the treatment of prostate cancer.


  • Open Access

    Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor γ

    by David A. Sarruf, Irena Iankova, Anna Abella, Said Assou, Stéphanie Miard, Lluis Fajas

    In addition to their role in cell cycle progression, new data reveal an emerging role of D-type cyclins in transcriptional regulation and cellular differentiation processes. Using 3T3-L1 cell lines to study adipogenesis, we observed an up-regulation of cyclin D3 expression throughout the differentiation process. Surprisingly, cyclin D3 was only minimally expressed during the initial stages of adipogenesis, when mitotic division is prevalent. This seemingly paradoxical expression led us to investigate a potential cell cycle-independent role for cyclin D3 during adipogenesis. We show here a direct interaction between cyclin D3 and the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). Our experiments reveal cyclin D3 acts as a ligand-dependent PPARγ coactivator, which, together with its cyclin-dependent kinase partner, phosphorylates the A-B domain of the nuclear receptor. Overexpression and knockdown studies with cyclin D3 had marked effects on PPARγ activity and subsequently on adipogenesis. Chromatin immunoprecipitation assays confirm the participation of cyclin D3 in the regulation of PPARγ target genes. We show that cyclin D3 mutant mice are protected from diet-induced obesity, display smaller adipocytes, have reduced adipogenic gene expression, and are insulin sensitive. Our results indicate that cyclin D3 is an important factor governing adipogenesis and obesity.


  • Open Access

    The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene

    by Jean-Sébastien Annicotte, Carine Chavey, Nadège Servant, Jacques Teyssier, Aurélie Bardin, Anne Licznar, Eric Badia, Pascal Pujol, Françoise Vignon, Thierry Maudelonde, et al.

    Liver receptor homolog-1 (LRH-1) is a nuclear receptor previously known to have distinct functions during mouse development and essential roles in cholesterol homeostasis. Recently, a new role for LRH-1 has been discovered in tumor progression, giving LRH-1 potential transforming functions. In order to identify critical factors stimulating LRH-1 expression leading to deregulated cellular proliferation, we studied its expression and its regulation in several breast cancer cell lines. We observed that LRH-1 expression was increased in estrogen receptor (ER) α expressing cell lines, whereas weak-to-no expression was found in nonexpressing ERα cell lines. In MCF7, LRH-1 expression was highly induced after treatment with 17β-estradiol (E2). This transcriptional regulation was the result of a direct binding of the ER to the LRH-1 promoter, as demonstrated by gelshift and chromatin immunoprecipitation assays. Interestingly, siRNA-mediated inactivation of LRH-1 decreased the E2-dependent proliferation of MCF7 cells. Finally, LRH-1 protein expression was detected by immunohistochemistry in tumor cells of human mammary ductal carcinomas. Altogether, these data demonstrate that LRH-1 is transcriptionally regulated by the ER α and reinforce the hypothesis that LRH-1 could exert potential oncogenic effects during breast cancer formation.


  • Atypical transcriptional regulators and cofactors of PPARγ

    by S Miard, L Fajas

    Regulation of peroxisome proliferator-activated receptor gamma (PPAR) activity is the result of several events. The first control level is the regulation of the expression of PPAR. Examples of this regulation, during adipogenesis, is the transactivation of the PPAR promoter by transcription factors of the classical pathway, such as C/EBPs or ADD1/SREBP1, but also newly identified factors, such as E2Fs. When preadipocytes re-enter the cell cycle, PPAR expression is induced coincident with an increase in DNA synthesis, suggesting the involvement of the E2F family of cell cycle regulators. E2F1 induces PPAR transcription during clonal expansion, whereas E2F4 represses PPAR expression during terminal adipocyte differentiation. Hence, E2Fs represent the link between proliferative signaling pathways, triggering clonal expansion, and terminal adipocyte differentiation through regulation of PPAR expression. A second regulatory level of PPAR action is interaction with cofactors. We will focus our attention on the atypical PPAR modulators. We have described an interaction between PPAR and the retinoblastoma protein, RB, which is both dependent upon ligand binding by PPAR and upon the phosphorylation status of RB. The interaction between PPAR and RB decreases the transcriptional activity of PPAR through recruitment of the histone deacetylase HDAC3. Inhibition of HDAC activity consequently results in a strong activation of PPAR.


  • Adipogenesis: a cross-talk between cell proliferation and cell differentiation

    by Lluis Fajas

    The transition between cell proliferation and cell differentiation taking place during adipocyte differentiation is a tightly regulated process where both cell cycle regulators and differentiating factors interact, creating a cascade of events leading to the commitment of the cells into the adipocyte phenotype. Based on in-vitro cell models of adipocyte differentiation, the different stages of adipogenesis have been established, each of them with a particular pattern of gene expression. Re-entry into the cell cycle of growth-arrested preadipocytes is known as the clonal expansion phase. Growth-arrested preadipocytes undergo several rounds of cell cycle before terminally differentiating into adipocytes, suggesting that a cross-talk might exist between the cell cycle or the cell proliferation machinery and the factors controlling cell differentiation. I will focus this review on the influence of the proliferative phase of preadipocytes in the adipocyte differentiation process.